CRISPR Therapeutics

CRSP

Market cap $5B

Recently, Zacks.com users have been paying close attention to CRISPR Therapeutics (CRSP). This makes it worthwhile to examine what the stock has in store.

CRISPR Therapeutics AG (CRSP) closed the most recent trading day at $53.35, moving 5.31% from the previous trading session.

CRISPR Therapeutics is a good pick to ride the gene editing revolution. The company boasts multiple catalysts on the way and an approved product with a large addressable market.

Gene-editing is a handy tool for developing sophisticated medicines. A new CRISPR molecule can destroy cells that express specific signals.

CRISPR Therapeutics AG (CRSP) closed at $60.77 in the latest trading session, marking a -1.81% move from the prior day.

CRISPR Therapeutics has developed a cutting-edge gene-editing biotechnology. Unlike many of its peers, CRISPR has plenty of developmental funding for the next few years.

Subscribers to our Substack, The Contrarian Edge , received this commentary on Sunday, July 5.

CRISPR Therapeutics AG has successfully launched Casgevy, the first FDA-approved CRISPR-based gene therapy. Viking Therapeutics is a development-stage company in the high-growth obesity drug market with a promising clinical pipeline.

CRISPR Therapeutics has transitioned to the commercial stage with the first approved CRISPR-based gene therapy. Viking Therapeutics maintains a high-potential pipeline focused on the rapidly expanding obesity and metabolic disorder markets.

CRISPR Therapeutics confirmed a dual breakout from inverse head and shoulders patterns, strengthening the bullish outlook and pointing to additional upside if resistance continues to give way.